摘要
目的克隆人血管生成素1基因(hAng1),采用AdMax包装系统构建含人血管生成素1的重组腺病毒质粒,为研究血管生成素1对急性肺损伤中炎症消退的作用奠定基础。方法将hAng1 cDNA克隆于真核表达载体pDC315-EGFP,得到重组质粒pDC315-EGFP-Ang1,采用位点特异性重组系统(Cre/Loxp)将pDC315-EGFP-Angl与pBHG lox△E1,3Cre辅助包装质粒共转染至HEK293细胞,生成带有Angl基因的重组腺病毒载体Ad-EGFP-Ang1,重组腺病毒质粒在HEK293细胞中扩增,氯化铯梯度离心纯化。检测转染的HEK293细胞中以及细胞培养上清中的Ang1蛋白表达。结果经酶切鉴定和测序证实载体构建的正确性,病毒滴度为1.5×1012 PFU·mL-1。Ad-EGFP-Ang1转染的HEK293细胞和细胞培养上清中均检测出Ang1蛋白。结论带有hAng1 cDNA的重组腺病毒载体构建成功,可用于对急性肺损伤炎症消退的影响的研究。
目的气管滴入脂多糖复制小鼠急性肺损伤模型,为进一步探讨炎症反应过程奠定基础。方法将20只SPF级雄性BALB/c小鼠(20-25g)随机分为对照组和脂多糖组,每组10只小鼠,麻醉后分别经气管插管滴入生理盐水(对照组)和脂多糖3mg·kg-1(脂多糖组)。观察24小时死亡率、肺组织湿干重比、病理改变,肺泡灌洗液中的白细胞计数、中性粒细胞计数和总蛋白浓度。结果脂多糖组小鼠死亡率33.3%,对照组没有小鼠死亡。脂多糖组肺组织病理评分、肺组织湿干重比、肺泡灌洗液中的白细胞计数、中性粒细胞计数和总蛋白浓度均高于对照组,(P=0.001)。结论气管滴入脂多糖3 mg·kg-1成功模拟了ALI的过程,是进一步探讨炎症反应过程的可靠的ALI动物模型。
目的通过基因转染增加血清中血管生成素1(Angl)的浓度,探讨血管生成素1基因治疗对急性肺损伤炎症消退的影响。方法SPF级BALB/c小鼠气管内滴入脂多糖构建急性肺损伤动物模型前,经尾静脉注入空载体病毒(Ad-GFP, GFP组)或者携带血管生成素1的腺病毒(Ad-GFP-Ag1, Ang1组)。经气管滴入脂多糖后4h、12h、24h、48h、72h、96h处死小鼠,取肺泡灌洗液收集细胞,行细胞计数分类,并用流式检测中性粒细胞凋亡和被巨噬细胞吞噬情况。收集肺组织和肝脏组织以及血清,检测血管生成素1的基因和蛋白表达。检测肺泡灌洗液中的粒细胞巨噬细胞集落刺激因子浓度变化。另外取4只小鼠,静脉注入空载体病毒,24小时后气管滴入生理盐水作对照组。结果LPS气管滴入后大量的白细胞浸润到肺组织和肺泡腔,早期以中性粒细胞为主,在48h白细胞和中性粒细胞达到最大值。Angl预处理增加了angl在肝脏的表达,分泌到血清中,减少了炎性细胞浸润并促进了中性粒细胞的凋亡和吞噬,从而加速了中性粒细胞从组织的清除,同时,增加了肺泡灌洗液中的粒细胞单核细胞集落刺激因子浓度。结论血管生成素1预处理促进了急性肺损伤炎症消退,这与其促进中性粒细胞的凋亡和巨噬细胞吞噬有关。
1经颈透照明视下完成并证实小鼠气管插管成功,经气管插管滴入3mg·kg-1脂多糖可以成功复制ALI模型。
2脂多糖3mg·kg-1气管滴入后48小时,肺组织炎症达高峰,随后进入炎症消退期。血管生成素1预处理有效的稳定血管内皮细胞,减少蛋白渗出,抑制了炎症细胞组织浸润。
3血管生成素1促进了急性肺损伤炎症消退。其机制是血管生成素1通过稳定血管内皮细胞促进炎症组织中性粒细胞凋亡,促进巨噬细胞吞噬凋亡的中性粒细胞。
4血管内皮细胞参与了炎症消退过程。
5血管内皮细胞可能是急性肺损伤防治的一个重要的潜在的靶点。
Objective To construct the recombinant adenovirus carrying human Angl (hAngl) in order to explore the effect of Angl on the inflammation resolution of acute lung injury induced by lipopolysaccharide. Methods The cDNA of hAngl was cloned into adenovirus shuttle vector pDC315-EGFP by standard procedure to obtain the recombinant adenoviral plasmid pDC315-EGFP-Ang1. Genomic plasmid pBHG lox AE1,3 Cre and pDC315-EGFP-Angl were cotransfected into 293 cells by using site-specific recombinant system Cre/Lox. The Ad-EGFP-hAngl recombinant adenovirus vector bearing hAngl was then amplified in 293 cells and purified by cesium chloride. The hAngl protein in the transfected HEK 293 cells and the medium of transfented HEK293 cells were detected by western blot and Elisa respectively. Results The cloned hAngl cDNA was confirmed correction by sequencing and enzyme cutting. The titer of Ad-GFP-hAngl was 1.50×1012 PFU·mL-1. The hAngl protein was detected in the Ad-GFP-hAngl transfected HEK 293 cells and time-dependent expressed in the medium of Ad-GFP-hAngl transfented HEK293 cells. Conclusion The recombinant adenovirus carrying human hAngl was successfully constructed by this method and ex vivo assays suggested the expression of human Angl with high efficiency and specificity.
Objective To establish a model of acute lung injury (AL1) in mice by LPS intratracheal instillation for studying the inflammation process. Methods Twenty male SPF BALB/c mice weighing 20-25g were randomly divided into two groups:Normal saline group (Control group) and lipopolysaccharide group(LPS group) with 10 mice in each group. Control group and LPS group received intratracheal injection of 2 mL·kg-1 normal saline or 3 mg·kg-1 popolysaccharide. All the mice were killed at 24 hours after injection. The wet-to-dry ratio and pathological change of lung were examined. In addition, the Leukocyte, PMN count and the total protein in BALwere analyzed with the incidence of mortality of each group observed. Results 3 mice died in the LPS group except one that was mis-intubated into the esophagus while no mouse died in the control group (P=0.001). The pathologic score of lung, the leukocyte, PMN and total protein in the BAL of the LPS group were significantly higher with the pathologic score of lung lower than that of the control group. Conclusion It is successful to imitate the development of ALI by injection of lipopolysaccharide. This is a suitable model for the following study of ALI in mice.
Objective:To investigate the effect of angiopoietinl on the inflammation resolution in acute lung injury. Methods:Animals were randomly assigned to GFP/saline group (control group), Ad-GFP/LPS group (GFP group) and Ad-GFP-Ang1/LPS group (Angl group).3-4 mice in GFP or Angl group were killed at 4 h,12 h,24 h,48 h,72 h and 96 h respectively. The cells in the BAL were counted and differentiated. The inflammation resolution indices between the GFP group and the Angl group were analyzed. Apoptotic polymorphonuclear leucocyte and its phagocytosis by macrophage cells were determined by fluorescent activated cell sorter. The angiopoietin-1 in serum and the Granulocyte macrophage colony-stimulating factor levels in the BAL were assayed following the manufacturer's instructions. Results:ALI for 4 h,12 h,24 h,48 h,72 h and 96 h induced evident leukocytes infiltration into the lung tissues, with a maximal infiltration (13.5×106) at 48 h. Pretreatment with adenovirus-GFP-angiopoietinl markedly increased serum Angl, reduced the leukocytes and polymorphonuclear cells infiltration and shortened the time interval from the maximal PMN point to the 50% reduction point (Ri) in inflammation resolution compared with the GFP group. At the same time, pretreatment with Ad-GFP significantly promoted the apoptosis of PMN cells and its clearance by macrophage cells. GMCSF levels in the BAL were augmentated without altering the time course in Angl group. Conclusions:This study provides evidence, for the first time, that angiopoietin-1 pretreatment promotes inflammation resolution of endotoxin-induced ALI in mice.
1. It is successful to imitate the development of ALI by intratracheal injection of lipopolysaccharide at the dose of 3 mg·kg-1. This is a suitable model for the following study of ALI in mice.
2. The PMN infiltration into the lung tissue in the ALI mice reached maximum at 48 hours after intratracheal injection of lipopolysaccharide at dose of 3 mg·kg-1. Then the inflammation resoluted and the PMN number in the BAL gradually reduced. Pretreatment with Ad-GFP-Angl significantly reduced the PMN infiltration and protein exudation by stabilizing the endothelium cells.
3. Pretreatment with Ad-GFP-Angl promoted the inflammation resolution of ALI. The mechanism is that the Angl accelerated the apoptosis of PMN in the tissues and the phagocytosis of apoptotic PMN by macrophage cells.
4. The endothelium cell takes part in the inflammation resolution.
5. The endothelium cell is perhaps an important potential target in pretreatment and treatment of ALI.
引文
[1]Nathan C. Points of control in inflammation [J]. Nature,2002,420 (6917):846-852.
[2]Lewis RA, Austen KF. Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds [J]. Nature,1981,293 (5828): 103-108.
[3]Gilroy DW, Lawrence T, Perretti M et al. Inflammatory resolution:new opportunities for drug discovery [J]. Nat Rev Drug Discov,2004,3 (5):401-416.
[4]Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation:dual anti-inflammatory and pro-resolution lipid mediators [J]. Nat Rev Immunol,2008,8 (5):349-361.
[5]Serhan CN. Systems approach to inflammation resolution:identification of novel anti-inflammatory and pro-resolving mediators [J]. J Thromb Haemost,2009,7 Suppl 1:44-48.
[6]Serhan CN, Brain SD, Buckley CD et al. Resolution of inflammation:state of the art, definitions and terms [J]. FASEB J,2007,21 (2):325-332.
[7]Bannenberg GL, Chiang N, Ariel A et al. Molecular circuits of resolution:formation and actions of resolvins and protectins [J]. J Immunol,2005,174 (7):4345-4355.
[8]Harris JF, Aden J, Lyons CR et al. Resolution of LPS-induced airway inflammation and goblet cell hyperplasia is independent of IL-18 [J]. Respiratory research,2007,8 (24):24-36.
[9]Cook-Mills JM, Deem TL. Active participation of endothelial cells in inflammation [J]. J Leukoc Biol,2005,77 (4):487-495.
[10]胥 楠,陈晓理.炎症过程中内皮细胞的功能变化及其后果[J].国际外科学杂志,2005,32(1)：21-25.
[11]Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and in the. pathophysiology of vascular disorders [J]. Blood,1998,91 (10):3527-3561.
[12]Johnson-Leger C, Imhof BA. Forging the endothelium during inflammation:pushing at a half-open door? [J]. Cell and tissue research,2003,314 (1):93-105.
[13]Luo HR, Loison F. Constitutive neutrophil apoptosis:mechanisms and regulation [J]. Am J Hematol,2008,83 (4):288-295.
[14]Akgul C, Moulding DA, Edwards SW. Molecular control of neutrophil apoptosis [J]. FEBS Lett,2001,487 (3):318-322.
[15]Zimmerman GA, Albertine KH, Carveth HJ et al. Endothelial activation in ARDS [J]. Chest,1999,116 (1 Suppl):18S-24S.
[16]Abraham E, Albert R, M. A. Round table conference. Acute lung injury [J]. Am J Respir Crit Care Med,1998,158 (2):675-679.
[17]Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off [J]. Nat Med, 2006,12 (2):171-172.
[18]Daly C, Wong V, Burova E et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) [J]. Genes Dev,2004, 18 (9):1060-1071.
[19]McCarter SD, Mei SH, Lai PF et al. Cell-based angiopoietin-1 gene therapy for acute lung injury [J]. Am J Respir Crit Care Med,2007,175 (10):1014-1026.
[20]Huang YQ, Sauthoff H, Herscovici P et al. Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury [J]. Crit Care Med,2008,36 (1):262-267.
[1]Anderson WE Human gene therapy [J]. Science,1992,256 (5058):808-813.
[2]Miller AD. Human gene therapy comes of age [J]. Nature,1992,357 (6378):455-460.
[3]Mulligan RC. The basic science of gene therapy [J]. Science,1993,260 (5110): 926-932.
[4]El-Aneed A. An overview of current delivery systems in cancer gene therapy [J]. J Control Release,2004,94 (1):1-14.
[5]VandenDriessche T, Vanslembrouck V, Goovaerts I et al. Long-term expression of human coagulation factor Ⅷ and correction of hemophilia A after in vivo retroviral gene transfer in factor Ⅷ-deficient mice [J]. Proc Natl Acad Sci U S A,1999,96 (18): 10379-10384.
[6]Connelly S, Smith TA, Dhir G et al. In vivo gene delivery and expression of physiological levels of functional human factor Ⅷ in mice [J]. Human gene therapy, 1995,6 (2):185-193.
[7]Moorhead JW, Clayton GH, Smith RL et al. A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears [J]. Journal of virology,1999,73 (2):1046-1053.
[8]Lusky M, Christ M, Rittner K et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted [J]. Journal of virology,1998, 72 (3):2022-2032.
[9]Lou J, Manske PR, Aoki M et al. Adenovirus-mediated gene transfer into tendon and tendon sheath [J]. J Orthop Res,1996,14 (4):513-517.
[10]Mitani K, Graham FL, Caskey CT et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector [J]. Proc Natl Acad Sci U S A,1995,92 (9):3854-3858.
[11]Puntel M, Curtin JF, Zirger JM et al. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time
polymerase chain reaction [J]. Human gene therapy,2006,17 (5):531-544.
[12]Stone D, Lieber A. New serotypes of adenoviral vectors [J]. Current opinion in molecular therapeutics,2006,8 (5):423-431.
[13]Cai G, Nie X, Guo P et al. A new inducible adenoviral expression system that responds to inflammatory stimuli in vivo [J]. The journal of gene medicine,2006,8 (12): 1369-1378.
[14]Ulasov IV, Tyler MA, Han Y et al. Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma [J]. Human gene therapy,2007,18 (2):118-129.
[15]Matthews DA, Cummings D, Evelegh C et al. Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein [J]. The Journal of general virology,1999,80 (Pt 2): 345-353.
[16]齐桓.以AdMax载体系统构建和制备肾癌相关抗原G250基因重组腺病毒表达载体[J].南方医科大学学报,2008,28(9)：1617-1620.
[17]Chalfie M, Tu Y, Euskirchen G et al. Green fluorescent protein as a marker for gene expression [J]. Science,1994,263 (5148):802-805.
[18]Paquin A, Jaalouk DE, Galipeau J. Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications [J]. Human gene therapy,2001, 12(1):13-23.
[1]Moss M, Goodman PL, Heinig M et al. Establishing the relative accuracy of three new definitions of the adult respiratory distress syndrome [J]. Crit Care Med,1995,23 (10): 1629-1637.
[2]Zhao X, Wu N, Zhou J et al. A technique for retrograde intubation in mice [J]. Lab animal,2006,35 (3):39-42.
[3]Rivera B, Miller S, Brown E et al. A novel method for endotracheal intubation of mice and rats used in imaging studies [J]. Contemp Top Lab Anim Sci,2005,44 (2):52-55.
[4]Derks CM, Jacobovitz-Derks D. Embolic pneumopathy induced by oleic acid. A systematic morphologic study [J]. Am J Pathol,1977,87 (1):143-158.
[5]Ware LB, Matthay MA. The acute respiratory distress syndrome [J]. N Engl J Med, 2000,342 (18):1334-1349.
[6]Balibrea JL, Arias-Diaz J. Acute respiratory distress syndrome in the septic surgical patient [J]. World journal of surgery,2003,27 (12):1275-1284.
[7]焦光宇,聂志伟,刘春利等.小剂量脂多糖气管内滴注制备急性肺损伤动物模型的探究[J].中国实验动物学报,2007,15(4)：292-295.
[8]Matthay MA, Zimmerman GA, Esmon C et al. Future research directions in acute lung injury:summary of a National Heart, Lung, and Blood Institute working group [J]. Am J Respir Crit Care Med,2003,167 (7):1027-1035.
[9]Sheng H, Laskowitz DT, Pearlstein RD et al. Characterization of a recovery global cerebral ischemia model in the mouse [J]. J Neurosci Methods,1999,88 (1):103-109.
[10]Akhter SA, Luttrell LM, Rockman HA et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy [J]. Science,1998,280 (5363):574-577.
[11]刘利辉,叶玲玉,谭渊明等.一种简捷可靠的小鼠气管插管新方法[J].中国医师 杂志,2006,8(8)：1019-1020.
[12]陶运明,莫绪明,戚继荣等.一种新的大鼠气管插管方法[J].中华试验外科杂志,2004,21(4)：504.
[13]Pelosi P, D'Onofrio D, Chiumello D et al. Pulmonary and extrapulmonary acute respiratory distress syndrome are different [J]. The European respiratory journal,2003, 42:48s-56s.
[14]Hoelz C, Negri EM, Lichtenfels AJ et al. Morphometric differences in pulmonary lesions in primary and secondary ARDS. A preliminary study in autopsies [J]. Pathology, research and practice,2001,197 (8):521-530.
[15]Kang JL, Lee HW, Lee HS et al. Genistein prevents nuclear factor-kappa B activation and acute lung injury induced by lipopolysaccharide [J]. Am J Respir Crit Care Med, 2001,164 (12):2206-2212.
[16]Martin TR. Direct lung injury by bacteria:clarifying the tools of the trade [J]. Crit Care Med,2004,32 (11):2360-2361.
[1]Liu D, Zeng BX, Zhang SH et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats [J]. Crit Care Med,2005,33 (10):2309-2316.
[2]Ware LB, Matthay MA. The acute respiratory distress syndrome [J]. N Engl J Med, 2000,342(18):1334-1349.
[3]Nathan C. Points of control in inflammation [J]. Nature,2002,420 (6917):846-852.
[4]Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation:dual anti-inflammatory and pro-resolution lipid mediators [J]. Nat Rev Immunol,2008,8 (5):349-361.
[5]Serhan CN, Brain SD, Buckley CD et al. Resolution of inflammation:state of the art, definitions and terms [J]. FASEB J,2007,21 (2):325-332.
[6]Zimmerman GA, Albertine KH, Carveth HJ et al. Endothelial activation in ARDS [J]. Chest,1999,116 (1 Suppl):18S-24S.
[7]Abraham E, Albert R, M. A. Round table conference. Acute lung injury [J]. Am J Respir Crit Care Med,1998,158 (2):675-679.
[8]Johnson-Leger C, Imhof BA. Forging the endothelium during inflammation:pushing at a half-open door? [J]. Cell and tissue research,2003,314 (1):93-105.
[9]Luo HR, Loison F. Constitutive neutrophil apoptosis:mechanisms and regulation [J]. Am J Hematol,2008,83 (4):288-295.
[10]Akgul C, Moulding DA, Edwards SW. Molecular control of neutrophil apoptosis [J]. FEBS Lett,2001,487 (3):318-322.
[11]McCarter SD, Mei SH, Lai PF et al. Cell-based angiopoietin-1 gene therapy for acute lung injury [J]. Am J Respir Crit Care Med,2007,175 (10):1014-1026.
[12]Kang JL, Lee HW, Lee HS et al. Genistein prevents nuclear factor-kappa B activation and acute lung injury induced by lipopolysaccharide [J]. Am J Respir Crit Care Med, 2001,164 (12):2206-2212.
[13]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method [J]. Methods,2001,25 (4): 402-408.
[14]Serhan CN, Savill J. Resolution of inflammation:the beginning programs the end [J]. Nat Immunol,2005,6 (12):1191-1197.
[15]Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off [J]. Nat Med, 2006,12 (2):171-172.
[16]Daly C, Wong V, Burova E et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) [J]. Genes Dev,2004, 18(9):1060-1071.
[17]Huang YQ, Sauthoff H, Herscovici P et al. Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury [J]. Crit Care Med,2008,36 (1):262-267.
[18]Karmpaliotis D, Kosmidou I, Ingenito EP et al. Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury [J]. Am J Physiol Lung Cell Mol Physiol,2002,283 (3):L585-595.
[19]Willnow TE, Sheng Z, Ishibashi S et al. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist [J]. Science,1994,264 (5164): 1471-1474.
[20]Thurston G, Rudge JS, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage [J]. Nat Med,2000,6(4):460-463.
[21]Bannenberg GL, Chiang N, Ariel A et al. Molecular circuits of resolution:formation and actions of resolvins and protectins [J]. J Immunol,2005,174 (7):4345-4355.
[22]Harris JF, Aden J, Lyons CR et al. Resolution of LPS-induced airway inflammation and goblet cell hyperplasia is independent of IL-18 [J]. Respiratory research,2007,8 (24):24-36.
[23]Matute-Bello G, Liles WC, Radella F,2nd et al. Neutrophil apoptosis in the acute respiratory distress syndrome [J]. Am J Respir Crit Care Med,1997,156 (6): 1969-1977.
[24]Cox G, Crossley J, Xing Z. Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary inflammation in vivo [J]. Am J Respir Cell Mol Biol,1995,12 (2):232-237.
[25]Matute-Bello G, Liles WC, Radella F,2nd et al. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome [J]. Crit Care Med, 2000,28 (1):1-7.
[1]Anggard EE, Botting RM, Vane JR. Endothelins [J]. Blood Vessels,1990,27 (2-5): 269-281.
[2]Cook-Mills JM, Deem TL. Active participation of endothelial cells in inflammation [J]. J Leukoc Biol,2005,77 (4):487-495.
[3]Reinhart K, Bayer O, Brunkhorst F et al. Markers of endothelial damage in organ dysfunction and sepsis [J]. Crit Care Med,2002,30 (5 Suppl):S302-312.
[4]Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders [J]. Blood,1998,91 (10):3527-3561.
[5]Anderson TJ. Assessment and treatment of endothelial dysfunction in humans [J]. J Am Coll Cardiol,1999,34 (3):631-638.
[6]Dejana E. Endothelial cell-cell junctions:happy together [J]. Nat Rev Mol Cell Biol, 2004,5 (4):261-270.
[7]Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions [J]. Circ Res, 2005,97 (6):512-523.
[8]Bazzoni G, Dejana E. Endothelial cell-to-cell junctions:molecular organization and role in vascular homeostasis [J]. Physiol Rev,2004,84 (3):869-901.
[9]Aird WC. Phenotypic heterogeneity of the endothelium:Ⅰ. Structure, function, and mechanisms [J]. Circ Res,2007,100 (2):158-173.
[10]Busse R, Fleming I. Vascular endothelium and blood flow [J]. Handb Exp Pharmacol, 2006 (176 Pt 2):43-78.
[11]Arnout J, Hoylaerts MF, Lijnen HR. Haemostasis [J]. Handb Exp Pharmacol,2006 (176 Pt 2):1-41.
[12]Moncada S, Higgs EA. Nitric oxide and the vascular endothelium [J]. Handb Exp Pharmacol,2006 (176 Pt 1):213-254.
[13]Minshall RD, Malik AB. Transport across the endothelium:regulation of endothelial permeability [J]. Handb Exp Pharmacol,2006 (176 Pt 1):107-144.
[14]Ley K, Reutershan J. Leucocyte-endothelial interactions in health and disease [J]. Handb Exp Pharmacol,2006 (176 Pt 2):97-133.
[15]Carmeliet P. Angiogenesis in health and disease [J]. Nat Med,2003,9 (6):653-660.
[16]Willms-Kretschmer K, Flax MH, Cotran RS. The fine structure of the vascular response in hapten-specific delayed hypersensitivity and contact dermatitis [J]. Lab Invest,1967,17 (3):334-349.
[17]Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell-cell interactions [J]. J Clin Invest,1997,100 (11 Suppl):S3-5.
[18]Pober JS. Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium. Physiology and pathology [J]. Am J Pathol,1988,133 (3): 426-433.
[19]Pober JS, Cotran RS. Cytokines and endothelial cell biology [J]. Physiol Rev,1990, 70 (2):427-451.
[20]Pober JS, Cotran RS. The role of endothelial cells in inflammation [J]. Transplantation, 1990,50 (4):537-544.
[21]Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation [J]. Nat Rev Immunol,2007,7 (10):803-815.
[22]Birch KA, Ewenstein BM, Golan DE et al. Prolonged peak elevations in cytoplasmic free calcium ions, derived from intracellular stores, correlate with the extent of thrombin-stimulated exocytosis in single human umbilical vein endothelial cells [J]. J
Cell Physiol,1994,160 (3):545-554.
[23]Stevens T, Garcia JG, Shasby DM et al. Mechanisms regulating endothelial cell barrier function [J]. Am J Physiol Lung Cell Mol Physiol,2000,279 (3):L419-422.
[24]Birch KA, Pober JS, Zavoico GB et al. Calcium/calmodulin transduces thrombin-stimulated secretion:studies in intact and minimally permeabilized human umbilical vein endothelial cells [J]. J Cell Biol,1992,118 (6):1501-1510.
[25]Lorant DE, Patel KD, McIntyre TM et al. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin:a juxtacrine system for adhesion and activation of neutrophils [J]. J Cell Biol,1991,115 (1):223-234.
[26]Brauner JS, Rohde LE, Clausell N. Circulating endothelin-1 and tumor necrosis factor-alpha:early predictors of mortality in patients with septic shock [J]. Intensive Care Med,2000,26 (3):305-313.
[27]Mavrommatis AC, Theodoridis T, Orfanidou A et al. Coagulation system and platelets are fully activated in uncomplicated sepsis [J]. Crit Care Med,2000,28 (2):451-457.
[28]Cribbs SK, Martin GS, Rojas M. Monitoring of endothelial dysfunction in critically ill patients:the role of endothelial progenitor cells [J]. Curr Opin Crit Care,2008,14 (3): 354-360.
[29]Coxon A, Tang T, Mayadas TN. Cytokine-activated endothelial cells delay neutrophil apoptosis in vitro and in vivo. A role for granulocyte/macrophage colony-stimulating factor [J]. J Exp Med,1999,190 (7):923-934.
[30]Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [J]. Cell,1996,87 (7):1161-1169.
[31]Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [J]. Science,1997,277 (5322):55-60.
[32]Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis [J]. Am J Pathol,1998, 153 (5):1459-1466.
[33]Sugimachi K, Tanaka S, Taguchi K et al. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma [J]. J Clin Pathol, 2003,56 (11):854-860.
[34]Schnurch H, Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage [J]. Development,1993,119 (3): 957-968.
[35]Partanen J, Armstrong E, Makela TP et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains [J]. Mol Cell Biol,1992,12 (4):1698-1707.
[36]Dumont DJ, Yamaguchi TP, Conlon RA et al. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors [J]. Oncogene,1992,7 (8):1471-1480.
[37]Sato TN, Qin Y, Kozak CA et al. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system [J]. Proc Natl Acad Sci U S A,1993,90 (20):9355-9358.
[38]Sato TN, Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation [J]. Nature,1995,376 (6535):70-74.
[39]Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases:VEGFs, angiopoietins, and ephrins in vascular development [J]. Genes Dev,1999,13 (9):1055-1066.
[40]Lee HJ, Cho CH, Hwang SJ et al. Biological characterization of angiopoietin-3 and angiopoietin-4 [J]. FASEB J,2004,18 (11):1200-1208.
[41]Wong AL, Haroon ZA, Werner S et al. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues [J]. Circ Res,1997,81 (4):567-574.
[42]Tsigkos S, Zhou Z, Kotanidou A et al. Regulation of Ang2 release by PTEN/PI3-kinase/Akt in lung microvascular endothelial cells [J]. J Cell Physiol,2006, 207 (2):506-511.
[43]Daly C, Wong V, Burova E et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) [J]. Genes Dev,2004, 18(9):1060-1071.
[44]Hughes DP, Marron MB, Brindle NP. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2 [J]. Circ Res,2003,92 (6):630-636.
[45]Jeon BH, Khanday F, Deshpande S et al. Tie-ing the antiinflammatory effect of angiopoietin-1 to inhibition of NF-kappaB [J]. Circ Res,2003,92 (6):586-588.
[46]Tadros A, Hughes DP, Dunmore BJ et al. ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1 [J]. Blood,2003,102 (13): 4407-4409.
[47]Thurston G, Suri C, Smith K et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1 [J]. Science,1999,286 (5449): 2511-2514.
[48]Thurston G, Rudge JS, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage [J]. Nat Med,2000,6 (4):460-463.
[49]Gamble JR, Drew J, Trezise L et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions [J]. Circ Res,2000,87 (7): 603-607.
[50]Kim I, Moon SO, Park SK et al. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression [J]. Circ Res,2001,89 (6):477-479.
[51]Haggstrom Rudolfsson S, Johansson A, Franck Lissbrant I et al. Localized expression of angiopoietin 1 and 2 may explain unique characteristics of the rat testicular microvasculature [J]. Biol Reprod,2003,69 (4):1231-1237.
[52]Karmpaliotis D, Kosmidou I, Ingenito EP et al. Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury [J]. Am J Physiol Lung Cell Mol Physiol,2002,283 (3):L585-595.
[53]Huang YQ, Sauthoff H, Herscovici P et al. Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury [J]. Crit Care Med,2008,36 (1):262-267.
[54]Melani C, Stoppacciaro A, Foroni C et al. Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis [J]. Cancer Immunol Immunother,2004,53 (7):600-608.
[55]Morrissey JH. Tissue factor:a key molecule in hemostatic and nonhemostatic systems [J]. Int J Hematol,2004,79 (2):103-108.
[56]Kim I, Oh JL, Ryu YS et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells [J]. FASEB J,2002,16 (1):126-128.
[57]Brown C, Gaspar J, Pettit A et al. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation [J]. J Biol Chem,2004,279 (13):12794-12803.
[58]Gerhauser I, Alldinger S, Baumgartner W. Ets-1 represents a pivotal transcription factor for viral clearance, inflammation, and demyelination in a mouse model of multiple sclerosis [J]. J Neuroimmunol,2007,188 (1-2):86-94.
[59]Tanaka K, Abe M, Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis [J]. Jpn J Cancer Res,1999,90 (6): 647-654.
[60]Sato Y, Abe M, Tanaka K et al. Signal transduction and transcriptional regulation of angiogenesis [J]. Adv Exp Med Biol,2000,476:109-115.
[61]Oda N, Abe M, Sato Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3 [J]. J Cell Physiol,1999,178 (2):121-132.
[62]Naito S, Shimizu S, Matsuu M et al. Ets-1 upregulates matrix metalloproteinase-1 expression through extracellular matrix adhesion in vascular endothelial cells [J]. Biochem Biophys Res Commun,2002,291 (1):130-138.
[63]Fiedler U, Reiss Y, Scharpfenecker M et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation [J]. Nat Med, 2006,12 (2):235-239.
[64]Kobayashi SD, Voyich JM, Whitney AR et al. Spontaneous neutrophil apoptosis and regulation of cell survival by granulocyte macrophage-colony stimulating factor [J]. J Leukoc Biol,2005,78 (6):1408-1418.
[65]Luo HR, Loison F. Constitutive neutrophil apoptosis:mechanisms and regulation [J]. Am J Hematol,2008,83 (4):288-295.
[66]Phillips GD, Whitehead RA, Knighton DR. Initiation and pattern of angiogenesis in wound healing in the rat [J]. Am J Anat,1991,192 (3):257-262.
[67]Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off [J]. Nat Med, 2006,12 (2):171-172.
[68]Monaco C, Andreakos E, Kiriakidis S et al. T-cell-mediated signalling in immune, inflammatory and angiogenic processes:the cascade of events leading to inflammatory diseases [J]. Curr Drug Targets Inflamm Allergy,2004,3(1):35-42.
[69]Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk:vascular endothelial growth factor is secreted by activated T cells and induces Thl polarization [J]. J Immunol,2004,172 (7):4618-4623.
[70]Gale NW, Thurston G, Hackett SF et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1 [J]. Dev Cell,2002,3 (3):411-423.
[71]Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor [J]. Endocr Rev,1997,18 (1):4-25.
[72]Benjamin LE, Golijanin D, Itin A et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J]. J Clin Invest,1999,103 (2):159-165.
[73]Karamysheva AF. Mechanisms of angiogenesis [J]. Biochemistry (Mosc),2008,73 (7): 751-762.
[74]Douglas IS, Nicolls MR. Chemokine-mediated angiogenesis:an essential link in the evolution of airway fibrosis? [J]. J Clin Invest,2005,115 (5):1133-1136.
[75]Lemieux C, Maliba R, Favier J et al. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses [J]. Blood,2005,105 (4): 1523-1530.
[76]Ren DC, Du GH, Zhang JT. High throughput screening for intercellular adhesion molecule-1 inhibitor [J]. Yao Xue Xue Bao,2003,38 (6):405-408.
[77]Hornig B, Arakawa N, Kohler C et al. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure [J]. Circulation,1998,97 (4): 363-368.
[78]Kugiyama K, Motoyama T, Doi H et al. Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels [J]. J Am Coll Cardiol,1999,33 (6):1512-1518.
[79]Heber D. Herbs and atherosclerosis [J]. Curr Atheroscler Rep,2001,3 (1):93-96.
[80]Ren D, Geng M, Du G et al. Polysaccharide sulfate 916 inhibits neutrophil-endothelial adhesion [J]. Chin Med J (Engl),2002,115 (12):1855-1858.
[81]Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction:clinical strategies for treating oxidant stress [J]. Am Heart J,2003,146 (2):218-226.
[82]Le Brocq M, Leslie SJ, Milliken P et al. Endothelial dysfunction:from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities [J]. Antioxid Redox Signal,2008,10 (9):1631-1674.
[83]Opar A. Where now for new drugs for atherosclerosis? [J]. Nat Rev Drug Discov, 2007,6 (5):334-335.